Generation and quality control of lipidomics data for the alzheimer’s disease neuroimaging initiative cohort

Alzheimer’s Disease Neuroimaging Initiative, Alzheimer’s Disease Metabolomics Consortium

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Abstract

Alzheimer’s disease (AD) is a major public health priority with a large socioeconomic burden and complex etiology. The Alzheimer Disease Metabolomics Consortium (ADMC) and the Alzheimer Disease Neuroimaging Initiative (ADNI) aim to gain new biological insights in the disease etiology. We report here an untargeted lipidomics of serum specimens of 806 subjects within the ADNI1 cohort (188 AD, 392 mild cognitive impairment and 226 cognitively normal subjects) along with 83 quality control samples. Lipids were detected and measured using an ultra-high-performance liquid chromatography quadruple/time-of-flight mass spectrometry (UHPLC-QTOF MS) instrument operated in both negative and positive electrospray ionization modes. The dataset includes a total 513 unique lipid species out of which 341 are known lipids. For over 95% of the detected lipids, a relative standard deviation of better than 20% was achieved in the quality control samples, indicating high technical reproducibility. Association modeling of this dataset and available clinical, metabolomics and drug-use data will provide novel insights into the AD etiology. These datasets are available at the ADNI repository at http://adni.loni.usc.edu/.

Original languageEnglish
Article number180263
JournalScientific data
Volume5
DOIs
StatePublished - 2018
Externally publishedYes

Fingerprint

Dive into the research topics of 'Generation and quality control of lipidomics data for the alzheimer’s disease neuroimaging initiative cohort'. Together they form a unique fingerprint.

Cite this